[go: up one dir, main page]

CY1108927T1 - Αναστολεις μιτωτικης κινεσινης - Google Patents

Αναστολεις μιτωτικης κινεσινης

Info

Publication number
CY1108927T1
CY1108927T1 CY20091100367T CY091100367T CY1108927T1 CY 1108927 T1 CY1108927 T1 CY 1108927T1 CY 20091100367 T CY20091100367 T CY 20091100367T CY 091100367 T CY091100367 T CY 091100367T CY 1108927 T1 CY1108927 T1 CY 1108927T1
Authority
CY
Cyprus
Prior art keywords
suspensions
mitotic kinesin
compounds
ksp kinesin
treating
Prior art date
Application number
CY20091100367T
Other languages
English (en)
Inventor
Paul J Coleman
Christopher D Cox
Robert M Garbaccio
George D Hartman
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of CY1108927T1 publication Critical patent/CY1108927T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά διϋδροπυρρολοενώσεις του Τύπου (I) που είναι χρήσιμες για την θεραπεία κυτταρικών πολλαπλασιαστικών ασθενειών, για την θεραπεία διαταραχών που σχετίζονται με δραστικότητα KSP κινεσίνης, και για την αναστολή KSP κινεσίνης. Η εφεύρεση επίσης αφορά συνθέσεις που περιλαμβάνουν αυτές τις ενώσεις, και μεθόδους χρήσης αυτών στην θεραπεία καρκίνου σε θηλαστικά.
CY20091100367T 2003-08-15 2009-03-30 Αναστολεις μιτωτικης κινεσινης CY1108927T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49563703P 2003-08-15 2003-08-15
US56358004P 2004-04-19 2004-04-19
EP04780791A EP1664026B1 (en) 2003-08-15 2004-08-11 Mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
CY1108927T1 true CY1108927T1 (el) 2014-07-02

Family

ID=34221386

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100367T CY1108927T1 (el) 2003-08-15 2009-03-30 Αναστολεις μιτωτικης κινεσινης

Country Status (15)

Country Link
US (2) US20060234984A1 (el)
EP (1) EP1664026B1 (el)
JP (1) JP4773961B2 (el)
AT (1) ATE421512T1 (el)
AU (1) AU2004266232B2 (el)
CA (1) CA2534065A1 (el)
CY (1) CY1108927T1 (el)
DE (1) DE602004019229D1 (el)
DK (1) DK1664026T3 (el)
ES (1) ES2319429T3 (el)
HR (1) HRP20090195T1 (el)
PL (1) PL1664026T3 (el)
PT (1) PT1664026E (el)
SI (1) SI1664026T1 (el)
WO (1) WO2005019206A1 (el)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
IL165624A0 (en) * 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
JP2007500219A (ja) * 2003-05-16 2007-01-11 アンビット バイオサイエンシス コーポレーション 複素環化合物およびその使用法
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
EP1656133A4 (en) 2003-08-15 2008-10-29 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
ES2319429T3 (es) * 2003-08-15 2009-05-07 MERCK & CO., INC. Inhibidores de cinesina mitotica.
CN1835756A (zh) 2003-08-15 2006-09-20 默克公司 有丝分裂驱动蛋白抑制剂
US20070225499A1 (en) * 2004-04-19 2007-09-27 Gary Javadi Process for the Preparation of 2,2-Disubstituted Pyrroles
JP2008505090A (ja) 2004-07-01 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤のプロドラッグ
US20100093767A1 (en) * 2004-12-03 2010-04-15 Takeda San Diego, Inc. Mitotic Kinase Inhibitors
US20080207693A1 (en) * 2005-03-16 2008-08-28 Coleman Paul J Mitotic Kinesin Inhibitors
EP1888050B1 (en) 2005-05-17 2012-03-21 Merck Sharp & Dohme Ltd. cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid for the treatment of cancer
CL2008003063A1 (es) 2007-10-19 2010-01-04 Schering Corp Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
PE20140858A1 (es) 2008-06-19 2014-08-04 Takeda Pharmaceutical Derivados de piperidina como inhibidores de renina
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
UA109417C2 (uk) 2009-10-14 2015-08-25 Мерк Шарп Енд Доме Корп. ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
LT2606134T (lt) 2010-08-17 2019-07-25 Sirna Therapeutics, Inc. Hepatito b viruso (hbv) geno raiškos slopinimas, tarpininkaujant rnr interferencijai naudojant mažą interferuojančią nukleorūgštį (sina)
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
JP5959541B2 (ja) * 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP2900241B1 (en) 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
SI2925888T1 (en) 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
CN104370939B (zh) * 2014-10-14 2016-10-26 上海交通大学 一种手性二氢吡咯类化合物的制备方法
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
EP3525785B1 (en) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5 inhibitors
SG11201908813QA (en) 2017-04-13 2019-10-30 Aduro Biotech Holdings Europe B V Anti-sirp alpha antibodies
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4076460A4 (en) 2019-12-17 2023-11-15 Merck Sharp & Dohme LLC PRMT5 INHIBITORS
CA3160153A1 (en) 2019-12-17 2021-06-24 Michelle Machacek Prmt5 inhibitors
WO2021126728A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112023025850A2 (pt) 2021-08-10 2024-03-05 Abbvie Inc Inibidores da nicotinamida ripk1

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3142699A (en) * 1958-04-24 1964-07-28 Bayer Ag Urethane compounds and process therefor
US3635982A (en) * 1969-04-08 1972-01-18 American Home Prod Amino-substituted-quinoxalinyloxazolidines and -oxazines
US4477389A (en) * 1982-10-25 1984-10-16 The United States Of America As Represented By The Secretary Of Agriculture Polyhalogenated phenyl isocyanate synthesis with excess phosgene and either triethylamine or tetramethylurea
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
AU4064597A (en) 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6440686B1 (en) * 2000-06-15 2002-08-27 Cytokinetics, Inc. Methods for screening and therapeutic applications of kinesin modulators
WO2003049527A2 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2003177052A (ja) * 2001-12-13 2003-06-27 Takata Corp シート重量計測装置
JP4399269B2 (ja) * 2002-03-08 2010-01-13 メルク エンド カムパニー インコーポレーテッド 有糸分裂性キネシン阻害薬
JP2005530806A (ja) * 2002-05-23 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害薬
CA2485343A1 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
IL165624A0 (en) * 2002-06-14 2006-01-15 Merck & Co Inc Mitotic kinesin inhibitors
ATE356804T1 (de) * 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
US6835899B2 (en) * 2002-08-21 2004-12-28 Trw Inc. Load sensing assembly for a vehicle seat
CA2500848A1 (en) * 2002-10-18 2004-05-06 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2004111193A2 (en) * 2003-06-12 2004-12-23 Merck & Co., Inc. Prodrugs of mitotic kinesin inhibitors
CA2527533A1 (en) * 2003-06-12 2004-12-29 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2005018638A1 (en) * 2003-08-13 2005-03-03 Merck & Co., Inc. Mitotic kinesin inhibitors
EP1656133A4 (en) * 2003-08-15 2008-10-29 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
ES2319429T3 (es) * 2003-08-15 2009-05-07 MERCK & CO., INC. Inhibidores de cinesina mitotica.
PE20050730A1 (es) * 2003-08-15 2005-09-20 Merck & Co Inc Derivados de 2,5-dihidropirrol 2,2-disustituidos como inhibidores de quinesinas mitoticas
US7294640B2 (en) * 2004-02-06 2007-11-13 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
JP4773961B2 (ja) 2011-09-14
HRP20090195T1 (hr) 2009-05-31
ES2319429T3 (es) 2009-05-07
DK1664026T3 (da) 2009-05-04
WO2005019206A1 (en) 2005-03-03
EP1664026B1 (en) 2009-01-21
PL1664026T3 (pl) 2009-06-30
ATE421512T1 (de) 2009-02-15
AU2004266232B2 (en) 2008-07-03
DE602004019229D1 (de) 2009-03-12
AU2004266232A1 (en) 2005-03-03
US20050043357A1 (en) 2005-02-24
PT1664026E (pt) 2009-04-23
US20060234984A1 (en) 2006-10-19
EP1664026A1 (en) 2006-06-07
SI1664026T1 (sl) 2009-04-30
US7465746B2 (en) 2008-12-16
CA2534065A1 (en) 2005-03-03
JP2007502774A (ja) 2007-02-15

Similar Documents

Publication Publication Date Title
CY1108927T1 (el) Αναστολεις μιτωτικης κινεσινης
DE60329756D1 (de) Mitotische kinesin-hemmer
ATE424388T1 (de) Mitotische kinesinhemmer
ATE447577T1 (de) Mitotische kinesin-hemmer
EP1463733A4 (en) INHIBITORS OF MITOTIC KINESINE
DE60329990D1 (de) Mitotische kinesin-hemmer
EP1515949A4 (en) INHIBITORS OF MITOTIC KINESINE
WO2005017190A3 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
WO2004037171A3 (en) Mitotic kinesin inhibitors
WO2004039774A3 (en) Mitotic kinesin inhibitors
WO2003099211A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2005065183A3 (en) Mitotic kinesin inhibitors
WO2005060654A3 (en) Mitotic kinesin inhibitors
NO20070589L (no) Mitotiske kinesin-inhibitorer.
WO2006031348A3 (en) Mitotic kinesin inhibitors
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
WO2006023440A3 (en) Mitotic kinesin inhibitors
WO2004087050A3 (en) Mitotic kinesin inhibitors